Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Locally advanced unresectable pancreatic ductal adenocarcinoma
Data

Cancers·Locally advanced unresectable pancreatic ductal adenocarcinoma

DataLocally advanced unresectable pancreatic ductal adenocarcinoma

Back to the Locally advanced unresectable pancreatic ductal adenocarcinoma hub →183 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Data

Related pages

183

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

Cancer
BRCA or PALB2-mutant pancreatic ductal adenocarcinoma
Shares NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV), Eileen M. O'Reilly, Daraxonrasib, Pancreatic cancer (KEGG map) and the tags subtype-page, gastrointestinal.
Cancer
Pancreatic acinar cell carcinoma
Shares Eileen M. O'Reilly, Whipple procedure (pancreaticoduodenectomy), Pancreatic cancer (KEGG map), KRAS wild-type pancreatic ductal adenocarcinoma and the tags subtype-page, gastrointestinal.
Cancer
Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors
Shares Obstructive jaundice and biliary obstruction, Resectable, borderline resectable and unresectable, CA 19-9, Whipple procedure (pancreaticoduodenectomy) and the tags subtype-page, gastrointestinal.
Cancer
Pancreatoblastoma
Shares Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it, Cancer cachexia, Whipple procedure (pancreaticoduodenectomy), Resection margins (R0 / R1 / R2) and the tags subtype-page, gastrointestinal.
Cancer
Localised anal squamous cell carcinoma (stage I to III)
Shares Chemoradiation (chemoradiotherapy, CRT), PET/CT, Fluorouracil (5-FU), Capecitabine and the tags subtype-page, gastrointestinal.
Cancer
Localised small bowel adenocarcinoma (stage I to III, resected)
Shares Whipple procedure (pancreaticoduodenectomy), KRAS, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Metastatic and recurrent anal squamous cell carcinoma
Shares Fluorouracil (5-FU), SBRT / SABR (stereotactic radiotherapy), Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Advanced and metastatic small bowel adenocarcinoma
Shares KRAS, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.

technologies

Biliary stenting and drainage Cytotoxic chemotherapy FAPI PET Hypofractionated radiotherapy Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)Irreversible electroporation (NanoKnife)KRAS & RAS inhibitors MR-guided adaptive radiotherapy Nutrition support and cachexia management PET/CT Platinum agents SBRT / SABR (stereotactic radiotherapy)Topoisomerase-I inhibitors (and ADC payloads)Tumour treating fields (TTFields)

targets

drugs

ApprovedOral fluoropyrimidine prodrug (antimetabolite)

Capecitabine · Xeloda

ApprovedSmall-molecule pan-RAS(ON) inhibitor

Daraxonrasib · Rasonque

ApprovedFluoropyrimidine antimetabolite

Fluorouracil (5-FU) · Adrucil / Efudex

ApprovedCytotoxic regimen

FOLFIRINOX / mFOLFIRINOX

ApprovedNucleoside analogue (deoxycytidine)

Gemcitabine · Gemzar / Infugem

ApprovedCytotoxic regimen

Gemcitabine + nab-paclitaxel · Gemzar + Abraxane

ApprovedCytotoxic regimen

NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) · Onivyde regimen

ApprovedDevice (tumour treating fields)

Optune / Optune Pax (TTFields) · Optune

EstablishedOral porcine pancreatic enzymes (lipase, protease, amylase) in enteric-coated capsules

Pancrelipase (pancreatic enzyme replacement therapy) · Creon, Nutrizym, Pancrease

Phase 2Small-molecule RAS(ON) G12D-selective inhibitor

companies

Eli Lilly (incl. Loxo)GERCOR Ipsen Mast Therapeutics Novocure Revolution Medicines Roche / Genentech

pathways

Cancer cachexia Fibroblast activation, desmoplasia & matrix stiffness Pancreatic cancer (KEGG map)

terms

CA 19-9 Cancer cachexia Chemoradiation (chemoradiotherapy, CRT)COMPASS: real-time sequencing of advanced pancreatic cancer for treatment selection Desmoplasia (tumour stroma)GATA6 as the marker of classical versus basal-like pancreatic cancer Locally advanced and locoregional disease Obstructive jaundice and biliary obstruction Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia Pancreatic cancer trials open today (registry snapshot and UK sites)Pancreatic cancer: the failed and stopped programmes and why Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it Resectability classes for pancreatic cancer (NCCN anatomical criteria and the 2017 international consensus)Resectable, borderline resectable and unresectable Resection margins (R0 / R1 / R2)Stenting (biliary, oesophageal, airway)Stereotactic body radiotherapy (SBRT / SABR)Vascular resection in pancreatic cancer surgery (portal and superior mesenteric vein resection; arterial resection)Whipple procedure (pancreaticoduodenectomy)

trials

A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Emboli A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metast A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic P A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Ca A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer Adebrelimab and Chidamide for Pancreatic Cancer Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer Albumin-bound Paclitaxel (II)-Combined Regimens for Pancreatic Cancer Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer Clinical Trial for Advanced or Metastatic Pancreatic Cancer Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer CONKO-003 (OFF)CONKO-007 CROSSFIRE Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer.Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer and 65 more →

ideas

Coverage-with-evidence registries for MR-guided and adaptive radiotherapy Losartan to loosen the stroma of pancreatic cancer before chemotherapy: a phase 3

people

Albert C. Koong Eileen M. O'Reilly Hedy L. Kindler Theodore S. Hong Theodore S. Lawrence Tobias Janowitz

key papers

Conroy 2011: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11)DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma LAP07: chemoradiotherapy versus continued chemotherapy for locally advanced pancreatic cancer controlled after four months of gemcitabine MPACT (Von Hoff 2013): nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-18. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

ProvenanceLast edited 2026-09-27 · Jude Gomila · The half a keyword search cannot find · diff · file

Wikipedia

Pancreatic cancer

Sources & links

Wikipedia
NCCN Guidelines: Pancreatic Adenocarcinoma

subtype-page gastrointestinal

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Locally advanced unresectable pancreatic ductal adenocarcinoma

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/locally-advanced-pdac/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id locally-advanced-pdac.

WebMCP tools registered on this page: onco_search, onco_get_entity.